B

BlossomHill Therapeutics

BLSMPro tracking

BlossomHill Therapeutics, Inc. · Nasdaq · Clinical-stage biotechnology · Research source · 424B4 · Research as of 2026/08/07 · Latest filing · 10-Q · 2026-11-12 SEC ↗ · SEC checked 2026-11-21

SEC
Saved research available · 424B4

BlossomHill Therapeutics offered 9,375,000 shares at $16.00 per share and expects to use net proceeds primarily for clinical development of its oncology drug candidates.

Research source · 424B4 · Research as of 2026/08/07Latest analyzed filing · 424B4 · 2026-08-07

Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.

SummaryWATCHReport source · 424B4

Newly listed — review valuation, deal quality and post-IPO supply before acting

A clinical-stage developer of small-molecule cancer medicines. The IPO priced at $16.00 and raised $150.00M.

Full source-backed summary

A clinical-stage developer of small-molecule cancer medicines. The IPO priced at $16.00 and raised $150.00M. The latest market-value reference is $501.94M; reported revenue is Pre-revenue and net result is $(71.09M). The offer figures are reconciled to the final prospectus.

Net loss($60,555,000)FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities($46,925,000)FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Voting controlNo controlling party conclusion availableNot separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
Business and development direction

A clinical-stage developer of small-molecule cancer medicines.

Current business

Clinical-stage biotechnology100%

Future development

Future direction not yet disclosed

DECISION DRIVERS

Key risks

High

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

High

Risk 2

The latest reported period remains loss-making.

High

Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

NEXT EVENTFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
LATEST EVIDENCE424B42026/08/07
LISTING CHECKPOINT2026-08-07Nasdaq
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualityThis saved report has no compatible source inputs for this calculation. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1J.P. Morgan Securities LLC38.00%3,562,500 shares
2Leerink Partners LLC28.00%2,625,000 shares
3Guggenheim Securities, LLC18.00%1,687,500 shares
4LifeSci Capital LLC9.00%843,750 shares
5H.C. Wainwright & Co., LLC7.00%656,250 shares

Ratio = institution commitment ÷ complete source-table total (9,375,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Number of shares

Number of shares

SEC table 598 row 10; source 1716297:1720150; SHA256 663a30bbd6c58f473c9d16e79e05554d57da88b92510fc93f83efd59022e95b2

J.P. Morgan Securities LLC: 3562500 / 9375000 × 100

Leerink Partners LLC: 2625000 / 9375000 × 100

Guggenheim Securities, LLC: 1687500 / 9375000 × 100

LifeSci Capital LLC: 843750 / 9375000 × 100

H.C. Wainwright & Co., LLC: 656250 / 9375000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.12$ / share
Total underwriting discount$10,500,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 7; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 7; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗

IPO CAPITAL QUALITY

Offering price $ / share$16
Gross offering amount $$150,000,000
Shares offered Shares9,375,000
Underwriting discount per share $ / share$1.12
Basis and evidence

No estimate is substituted for missing offer terms.

Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered9,375,000Shares
Offering price$16$ / share
Gross offering amount$150,000,000$
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 26 row 1; source 80140:80472; SHA256 0809dfe46127523e302b62dfe381fc27eebee8aa80610e9d127892b4a1e49ec3 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 5; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗
IPO investors$150.00Mgross offer size
Issuer / selling holdersSee 424Bprimary-secondary split
Reported revenuePre-revenue—
Net result$(71.09M)latest reported basis
Future supplyLock-upreview holder-specific terms

Dilution and valuation

IPO price$16Final
Basic post-offer≈ 30.6437M
Equity value≈ $490.2986M
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 30.6437M≈ $490.2986M
Derived calculationFinalshares · $Basis and evidence 10 ↗
Post-offer shares — base/no option30,643,660—
Reported sourcePost-offer · BasesharesBasis and evidence 8 ↗
Post-offer shares — full option32,049,910—
Reported sourcePost-offer · Full optionsharesBasis and evidence 8 ↗
Capitalization shares — actual2,644,326—
Reported sourceCommon stock; actualsharesBasis and evidence 3 ↗
Capitalization shares — pro forma21,268,660—
Reported sourceCommon stock; pro formasharesBasis and evidence 4 ↗
Capitalization shares — pro forma as adjusted30,643,660—
Reported sourceCommon stock; pro forma as adjustedsharesBasis and evidence 5 ↗
Shares offered9,375,000—
Reported sourcesharesBasis and evidence 6 ↗
Offering price—$16
Reported sourceFinal$/shareBasis and evidence 7 ↗
Gross offering amount—$150,000,000
Reported source$Basis and evidence 7 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 28 row 1 columns 2; share summary; label column 1; source 81122:81599; SHA256 cb5818ad2f29897427fd80d053186d195d33d6057b8e9f90b6a624604128a3e4 ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 28 row 1 columns 2; share summary; label column 1; source 81122:81599; SHA256 cb5818ad2f29897427fd80d053186d195d33d6057b8e9f90b6a624604128a3e4 ↗

Basis and evidence 3

Capitalization share count; source stage: actual; Common stock, $0.0001 par value; 110,000,000 shares authorized, 2,644,326 shares issued and outstanding, actual; 700,000,000 shares authorized, pro forma and pro forma as adjusted; 21,268,660 shares issued and outstanding, pro forma; 30,643,660 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 312 row 10 columns 1; share summary; label column 1; source 706874:716113; SHA256 94318238e84202b0dec0be71c60d3b8070641dfa20143c4977dd030d749b85e5 ↗

Basis and evidence 4

Capitalization share count; source stage: pro forma; Common stock, $0.0001 par value; 110,000,000 shares authorized, 2,644,326 shares issued and outstanding, actual; 700,000,000 shares authorized, pro forma and pro forma as adjusted; 21,268,660 shares issued and outstanding, pro forma; 30,643,660 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 312 row 10 columns 1; share summary; label column 1; source 706874:716113; SHA256 94318238e84202b0dec0be71c60d3b8070641dfa20143c4977dd030d749b85e5 ↗

Basis and evidence 5

Capitalization share count; source stage: pro forma as adjusted; Common stock, $0.0001 par value; 110,000,000 shares authorized, 2,644,326 shares issued and outstanding, actual; 700,000,000 shares authorized, pro forma and pro forma as adjusted; 21,268,660 shares issued and outstanding, pro forma; 30,643,660 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 312 row 10 columns 1; share summary; label column 1; source 706874:716113; SHA256 94318238e84202b0dec0be71c60d3b8070641dfa20143c4977dd030d749b85e5 ↗

Basis and evidence 6

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 26 row 1; source 80140:80472; SHA256 0809dfe46127523e302b62dfe381fc27eebee8aa80610e9d127892b4a1e49ec3 ↗

Basis and evidence 7

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 5; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗

Basis and evidence 8

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $16

Exact input · Post-offer shares — base/no option: 30,643,660

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 32,049,910

SEC table 1 row 5; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗

SEC table 28 row 1 columns 2; share summary; label column 1; source 81122:81599; SHA256 cb5818ad2f29897427fd80d053186d195d33d6057b8e9f90b6a624604128a3e4 ↗

SEC valuation primary issuer cover; source 1054:1387; SHA256 12f6efcafb909d31ad63c6dd7f409c841d2bfcefbd93e5111f7726cf311705fa ↗

SEC valuation summary conditions; source 76697:80070; SHA256 40d4554f8f5c5d00d547094e26ba83362b9f591e3146132296889129c79d0cbf ↗

SEC valuation summary conditions; source 85695:119745; SHA256 6c0223a6976965f7faaf8a3476da56faf46d1ba84540b6bc1c060676c36a2d1c ↗

Basis and evidence 10

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 30,643,660 shares (or 32,049,910 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 30,643,660

Exact input · Offering price: $16

SEC table 1 row 5; source 2065:5902; SHA256 a88a28c81a03f8ac1d36461ffb847f8cbbc852f05965045198cca81bc9c67c4f ↗

SEC table 28 row 1 columns 2; share summary; label column 1; source 81122:81599; SHA256 cb5818ad2f29897427fd80d053186d195d33d6057b8e9f90b6a624604128a3e4 ↗

SEC valuation primary issuer cover; source 1054:1387; SHA256 12f6efcafb909d31ad63c6dd7f409c841d2bfcefbd93e5111f7726cf311705fa ↗

SEC valuation summary conditions; source 76697:80070; SHA256 40d4554f8f5c5d00d547094e26ba83362b9f591e3146132296889129c79d0cbf ↗

SEC valuation summary conditions; source 85695:119745; SHA256 6c0223a6976965f7faaf8a3476da56faf46d1ba84540b6bc1c060676c36a2d1c ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $16 × ≈ 30.6437M shares · Final

Implied equity value≈ $490.2986MPrice × post-offer shares
Post-offer shares≈ 30.6437MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Prior saved context

These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.

IPO price · 9.375M · $150.00M · $16.00

Latest shares outstanding · 30.64M · $501.94M · Market snapshot

Revenue reference · — · Pre-revenue · —

Net-result reference · — · $(71.09M) · Loss-making

$16 × 30,643,660 = $490,298,560 [summary-table-28-base-1-price, summary-table-28-base-1-post]

Exact calculation · Derived whole-issuer equity value: $490,298,560

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesComparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗
CONTROLLING PARTYNo controlling party conclusion available

Latest available filing

Economic
~30.6%*
As of
2026/08/07
!Review the beneficial-ownership table and voting rights togetherView source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · BlossomHill Therapeutics
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
our executive officers, directors and stockholders whoOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partitionDisclosedEvidence
our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliatesOwnership as disclosed—approximately 41.8%Beneficial—
Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exerci; not an additive ownership partitionDisclosedEvidence
J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial shares3,973,138——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial shares3,973,138——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Entities affiliated with Cormorant Asset Management LPBeneficial shares3,301,534——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Entities affiliated with Cormorant Asset Management LPBeneficial shares3,301,534——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
OrbiMed Private Investments VIII, LPBeneficial shares2,089,279——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
OrbiMed Private Investments VIII, LPBeneficial shares2,089,279——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Vivo Innovation Fund II Holdings, L.P.Beneficial shares1,493,740——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Vivo Innovation Fund II Holdings, L.P.Beneficial shares1,493,740——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Janus Henderson Biotech Innovation Master Fund LimitedBeneficial shares1,134,361——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Janus Henderson Biotech Innovation Master Fund LimitedBeneficial shares1,134,361——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
J. Jean Cui, Ph.D.Beneficial shares3,973,138——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
J. Jean Cui, Ph.D.Beneficial shares3,973,138——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial ownership—18.7%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliatesBeneficial ownership—13%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Entities affiliated with Cormorant Asset Management LPBeneficial ownership—15.5%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Entities affiliated with Cormorant Asset Management LPBeneficial ownership—10.8%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
OrbiMed Private Investments VIII, LPBeneficial ownership—9.8%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
OrbiMed Private Investments VIII, LPBeneficial ownership—6.8%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Vivo Innovation Fund II Holdings, L.P.Beneficial ownership—7%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Vivo Innovation Fund II Holdings, L.P.Beneficial ownership—4.9%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Janus Henderson Biotech Innovation Master Fund LimitedBeneficial ownership—5.3%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Janus Henderson Biotech Innovation Master Fund LimitedBeneficial ownership—3.7%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
J. Jean Cui, Ph.D.Beneficial ownership—18.7%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
J. Jean Cui, Ph.D.Beneficial ownership—13%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Y. Peter Li, Ph.D., MBABeneficial shares3,973,138——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Y. Peter Li, Ph.D., MBABeneficial shares3,973,138——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Geoff Oxnard, M.D.Beneficial shares75,861——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Geoff Oxnard, M.D.Beneficial shares75,861——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Jason Keyes, MBABeneficial shares54,818——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Jason Keyes, MBABeneficial shares54,818——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Sundeep Agrawal, M.D.Beneficial shares589,195——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Sundeep Agrawal, M.D.Beneficial shares589,195——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Bihua Chen, MBABeneficial shares3,301,534——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Bihua Chen, MBABeneficial shares3,301,534——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial shares2,089,279——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial shares2,089,279——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
Y. Peter Li, Ph.D., MBABeneficial ownership—18.7%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Y. Peter Li, Ph.D., MBABeneficial ownership—13%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Sundeep Agrawal, M.D.Beneficial ownership—2.8%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Sundeep Agrawal, M.D.Beneficial ownership—1.9%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Bihua Chen, MBABeneficial ownership—15.5%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Bihua Chen, MBABeneficial ownership—10.8%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial ownership—9.8%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
Carl L. Gordon, Ph.D., CFABeneficial ownership—6.8%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial ownership—48.4%Beneficial—
Sharesbeneficially ownedprior to offering; PercentageDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial ownership—33.7%Beneficial—
Sharesbeneficially ownedafter offering; PercentageDisclosedEvidence
Sheila Gujrathi, M.D.Beneficial shares90,160——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
Sheila Gujrathi, M.D.Beneficial shares90,160——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
John Schmid, MBABeneficial shares67,620——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
John Schmid, MBABeneficial shares67,620——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial shares10,371,004——
Sharesbeneficially ownedprior to offering; NumberDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial shares10,371,004——
Sharesbeneficially ownedafter offering; NumberDisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retainedDisclosedEvidence
Source and calculation ↗
our executive officers, directors and stockholders who · our executive officers, directors and stockholders who — Ownership as disclosed · >5%

Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 41.8% of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-340215 · SEC ownership paragraph; source 614171:615786; SHA256 254985c98c4d5a5387fa3efb91bcf664bda3b38e9422b7c279e486f1dc07e8e4 ↗

our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates · our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates — Ownership as disclosed · approximately 41.8%

Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance); source scope: of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exerci; not an additive ownership partition

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold approximately 41.8% of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026 and assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options other than the Exercised Option Share Issuance). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-340215 · SEC ownership paragraph; source 614171:615786; SHA256 254985c98c4d5a5387fa3efb91bcf664bda3b38e9422b7c279e486f1dc07e8e4 ↗

J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates · J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates — Beneficial shares · 3,973,138

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)

0001193125-26-340215 · SEC table 540 row 6 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates · J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates — Beneficial shares · 3,973,138

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)

0001193125-26-340215 · SEC table 540 row 6 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Entities affiliated with Cormorant Asset Management LP · Entities affiliated with Cormorant Asset Management LP — Beneficial shares · 3,301,534

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Entities affiliated with Cormorant Asset Management LP(2)

0001193125-26-340215 · SEC table 540 row 7 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Entities affiliated with Cormorant Asset Management LP · Entities affiliated with Cormorant Asset Management LP — Beneficial shares · 3,301,534

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Entities affiliated with Cormorant Asset Management LP(2)

0001193125-26-340215 · SEC table 540 row 7 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

OrbiMed Private Investments VIII, LP · OrbiMed Private Investments VIII, LP — Beneficial shares · 2,089,279

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: OrbiMed Private Investments VIII, LP(3)

0001193125-26-340215 · SEC table 540 row 8 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

OrbiMed Private Investments VIII, LP · OrbiMed Private Investments VIII, LP — Beneficial shares · 2,089,279

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: OrbiMed Private Investments VIII, LP(3)

0001193125-26-340215 · SEC table 540 row 8 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Vivo Innovation Fund II Holdings, L.P. · Vivo Innovation Fund II Holdings, L.P. — Beneficial shares · 1,493,740

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Vivo Innovation Fund II Holdings, L.P.(4)

0001193125-26-340215 · SEC table 540 row 9 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Vivo Innovation Fund II Holdings, L.P. · Vivo Innovation Fund II Holdings, L.P. — Beneficial shares · 1,493,740

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Vivo Innovation Fund II Holdings, L.P.(4)

0001193125-26-340215 · SEC table 540 row 9 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Janus Henderson Biotech Innovation Master Fund Limited · Janus Henderson Biotech Innovation Master Fund Limited — Beneficial shares · 1,134,361

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)

0001193125-26-340215 · SEC table 540 row 10 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Janus Henderson Biotech Innovation Master Fund Limited · Janus Henderson Biotech Innovation Master Fund Limited — Beneficial shares · 1,134,361

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)

0001193125-26-340215 · SEC table 540 row 10 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

J. Jean Cui, Ph.D. · J. Jean Cui, Ph.D. — Beneficial shares · 3,973,138

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: J. Jean Cui, Ph.D.(1)

0001193125-26-340215 · SEC table 540 row 13 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

J. Jean Cui, Ph.D. · J. Jean Cui, Ph.D. — Beneficial shares · 3,973,138

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: J. Jean Cui, Ph.D.(1)

0001193125-26-340215 · SEC table 540 row 13 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates · J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates — Beneficial ownership · 18.7%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)

0001193125-26-340215 · SEC table 540 row 6 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates · J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates — Beneficial ownership · 13%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: J. Jean Cui, Ph.D. and Y. Peter Li, Ph.D., MBA and related affiliates(1)

0001193125-26-340215 · SEC table 540 row 6 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Entities affiliated with Cormorant Asset Management LP · Entities affiliated with Cormorant Asset Management LP — Beneficial ownership · 15.5%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Entities affiliated with Cormorant Asset Management LP(2)

0001193125-26-340215 · SEC table 540 row 7 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Entities affiliated with Cormorant Asset Management LP · Entities affiliated with Cormorant Asset Management LP — Beneficial ownership · 10.8%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Entities affiliated with Cormorant Asset Management LP(2)

0001193125-26-340215 · SEC table 540 row 7 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

OrbiMed Private Investments VIII, LP · OrbiMed Private Investments VIII, LP — Beneficial ownership · 9.8%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: OrbiMed Private Investments VIII, LP(3)

0001193125-26-340215 · SEC table 540 row 8 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

OrbiMed Private Investments VIII, LP · OrbiMed Private Investments VIII, LP — Beneficial ownership · 6.8%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: OrbiMed Private Investments VIII, LP(3)

0001193125-26-340215 · SEC table 540 row 8 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Vivo Innovation Fund II Holdings, L.P. · Vivo Innovation Fund II Holdings, L.P. — Beneficial ownership · 7%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Vivo Innovation Fund II Holdings, L.P.(4)

0001193125-26-340215 · SEC table 540 row 9 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Vivo Innovation Fund II Holdings, L.P. · Vivo Innovation Fund II Holdings, L.P. — Beneficial ownership · 4.9%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Vivo Innovation Fund II Holdings, L.P.(4)

0001193125-26-340215 · SEC table 540 row 9 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Janus Henderson Biotech Innovation Master Fund Limited · Janus Henderson Biotech Innovation Master Fund Limited — Beneficial ownership · 5.3%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)

0001193125-26-340215 · SEC table 540 row 10 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Janus Henderson Biotech Innovation Master Fund Limited · Janus Henderson Biotech Innovation Master Fund Limited — Beneficial ownership · 3.7%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Janus Henderson Biotech Innovation Master Fund Limited(5)

0001193125-26-340215 · SEC table 540 row 10 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

J. Jean Cui, Ph.D. · J. Jean Cui, Ph.D. — Beneficial ownership · 18.7%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: J. Jean Cui, Ph.D.(1)

0001193125-26-340215 · SEC table 540 row 13 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

J. Jean Cui, Ph.D. · J. Jean Cui, Ph.D. — Beneficial ownership · 13%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: J. Jean Cui, Ph.D.(1)

0001193125-26-340215 · SEC table 540 row 13 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Y. Peter Li, Ph.D., MBA · Y. Peter Li, Ph.D., MBA — Beneficial shares · 3,973,138

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Y. Peter Li, Ph.D., MBA(1)

0001193125-26-340215 · SEC table 540 row 14 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Y. Peter Li, Ph.D., MBA · Y. Peter Li, Ph.D., MBA — Beneficial shares · 3,973,138

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Y. Peter Li, Ph.D., MBA(1)

0001193125-26-340215 · SEC table 540 row 14 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Geoff Oxnard, M.D. · Geoff Oxnard, M.D. — Beneficial shares · 75,861

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Geoff Oxnard, M.D.(6)

0001193125-26-340215 · SEC table 540 row 15 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Geoff Oxnard, M.D. · Geoff Oxnard, M.D. — Beneficial shares · 75,861

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Geoff Oxnard, M.D.(6)

0001193125-26-340215 · SEC table 540 row 15 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Jason Keyes, MBA · Jason Keyes, MBA — Beneficial shares · 54,818

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Jason Keyes, MBA(7)

0001193125-26-340215 · SEC table 540 row 16 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Jason Keyes, MBA · Jason Keyes, MBA — Beneficial shares · 54,818

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Jason Keyes, MBA(7)

0001193125-26-340215 · SEC table 540 row 16 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Sundeep Agrawal, M.D. · Sundeep Agrawal, M.D. — Beneficial shares · 589,195

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Sundeep Agrawal, M.D.(8)

0001193125-26-340215 · SEC table 540 row 17 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Sundeep Agrawal, M.D. · Sundeep Agrawal, M.D. — Beneficial shares · 589,195

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Sundeep Agrawal, M.D.(8)

0001193125-26-340215 · SEC table 540 row 17 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Bihua Chen, MBA · Bihua Chen, MBA — Beneficial shares · 3,301,534

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Bihua Chen, MBA(9)

0001193125-26-340215 · SEC table 540 row 18 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Bihua Chen, MBA · Bihua Chen, MBA — Beneficial shares · 3,301,534

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Bihua Chen, MBA(9)

0001193125-26-340215 · SEC table 540 row 18 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial shares · 2,089,279

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Carl L. Gordon, Ph.D., CFA(10)

0001193125-26-340215 · SEC table 540 row 19 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial shares · 2,089,279

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Carl L. Gordon, Ph.D., CFA(10)

0001193125-26-340215 · SEC table 540 row 19 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

Y. Peter Li, Ph.D., MBA · Y. Peter Li, Ph.D., MBA — Beneficial ownership · 18.7%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Y. Peter Li, Ph.D., MBA(1)

0001193125-26-340215 · SEC table 540 row 14 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Y. Peter Li, Ph.D., MBA · Y. Peter Li, Ph.D., MBA — Beneficial ownership · 13%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Y. Peter Li, Ph.D., MBA(1)

0001193125-26-340215 · SEC table 540 row 14 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Sundeep Agrawal, M.D. · Sundeep Agrawal, M.D. — Beneficial ownership · 2.8%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Sundeep Agrawal, M.D.(8)

0001193125-26-340215 · SEC table 540 row 17 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Sundeep Agrawal, M.D. · Sundeep Agrawal, M.D. — Beneficial ownership · 1.9%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Sundeep Agrawal, M.D.(8)

0001193125-26-340215 · SEC table 540 row 17 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Bihua Chen, MBA · Bihua Chen, MBA — Beneficial ownership · 15.5%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Bihua Chen, MBA(9)

0001193125-26-340215 · SEC table 540 row 18 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Bihua Chen, MBA · Bihua Chen, MBA — Beneficial ownership · 10.8%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Bihua Chen, MBA(9)

0001193125-26-340215 · SEC table 540 row 18 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial ownership · 9.8%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: Carl L. Gordon, Ph.D., CFA(10)

0001193125-26-340215 · SEC table 540 row 19 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

Carl L. Gordon, Ph.D., CFA · Carl L. Gordon, Ph.D., CFA — Beneficial ownership · 6.8%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: Carl L. Gordon, Ph.D., CFA(10)

0001193125-26-340215 · SEC table 540 row 19 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial ownership · 48.4%

Exact source ownership column: Sharesbeneficially ownedprior to offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340215 · SEC table 540 row 23 columns 8; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:6 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial ownership · 33.7%

Exact source ownership column: Sharesbeneficially ownedafter offering; Percentage; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340215 · SEC table 540 row 23 columns 16; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:12 ↗

Sheila Gujrathi, M.D. · Sheila Gujrathi, M.D. — Beneficial shares · 90,160

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: Sheila Gujrathi, M.D.(11)

0001193125-26-340215 · SEC table 540 row 20 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

Sheila Gujrathi, M.D. · Sheila Gujrathi, M.D. — Beneficial shares · 90,160

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: Sheila Gujrathi, M.D.(11)

0001193125-26-340215 · SEC table 540 row 20 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

John Schmid, MBA · John Schmid, MBA — Beneficial shares · 67,620

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: John Schmid, MBA(12)

0001193125-26-340215 · SEC table 540 row 21 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

John Schmid, MBA · John Schmid, MBA — Beneficial shares · 67,620

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: John Schmid, MBA(12)

0001193125-26-340215 · SEC table 540 row 21 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial shares · 10,371,004

Exact source ownership column: Sharesbeneficially ownedprior to offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedprior to offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340215 · SEC table 540 row 23 columns 4; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:3,4:3 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial shares · 10,371,004

Exact source ownership column: Sharesbeneficially ownedafter offering; Number; holders may overlap; not an additive partition

Raw source column: Sharesbeneficially ownedafter offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340215 · SEC table 540 row 23 columns 12; source 1595198:1614778; SHA256 1793b37c65f57b8fa718bad9da807616c3c4404ee7acd200bda27edbc91f85f2; ownership header cells 3:6,4:9 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained

Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. There are no cumulative voting rights. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 700,000,000 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law (DGCL). This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the DGCL.

0001193125-26-340215 · SEC ownership excerpt; source 1632090:1632463; SHA256 20674e0ba9976428c19d734d28d462e3ed5b6aa7bf37d8aba22db6c241740483; context source 1629682:1630816; SHA256 840700b095b551cb9d1f29f39fcd038d7f07a91cf6496b5cac3f4eaf46ddf0dd ↗

Saved control snapshot

The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.

Saved control snapshot
Holder / measureSharesOwnershipVoting rightsReference
Existing holdersMajor ownership group—~69.4%*—
2026/08/07Latest available filing424B4 ↗
Other disclosed classesMajor ownership group—See filing—
2026/08/07Latest available filing424B4 ↗
IPO sharesPublic / new investors—9.375M—
2026/08/07Latest available filing424B4 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

POTENTIAL SUPPLY PRESSURERequires holder-level review

IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.

Initial float
9.375M
Restricted / potential supply
30.64M
Multiple
See filing
Increase
See filing

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
WeAfter date of this prospectus · Source conditions apply180 days
our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stockAfter date of this prospectus · Source conditions apply180 days
Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)After date of this prospectus · Source conditions apply180 days
Source and calculation
We

We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of the representatives for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.

SEC lock-up paragraph; source 1726871:1728068; SHA256 3ea74a57fdc13795fe958e943e03da473d45bde16e628d8f6147fa81b5e6eec4 ↗
our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stock

Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares of our common stock, could reduce the market price of our common stock. After this offering, we will have 30,643,660 shares of common stock outstanding (assuming no exercise of the underwriters’ option to purchase additional shares of our common stock). This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Substantially all of the remaining 21,268,660 shares of our common stock initially will be restricted as a result of securities laws, market standoff provisions or lock-up agreements, but will become eligible to be sold after this offering as described in the section titled “Shares eligible for future sale.” We, our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stock have entered into market standoff agreements with us and have entered or will enter into lock-up agreements under which we have agreed or will agree, subject to specific exceptions described in the section titled “Underwriting,” not to offer, sell, or transfer such securities for 180 days following the date of this prospectus. We refer to such period as the lock-up period. The underwriters may, in their sole discretion and at any time or from time to time before the termination of the lock-up period release all or any portion of the securities subject to lock-up agreements.

SEC lock-up paragraph; source 616114:618119; SHA256 9d2f9e293a170c8b33690af4a5864674d3365c0365bfe3c10d6d3b96c1b6b43b ↗
Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)

Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of the representatives, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including,

SEC lock-up paragraph; source 1730330:1731394; SHA256 37b6a51c29f7cefa63fe107ccf4ad1738116e37e2966d8168a6b8b8128a7da60 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Milestones and unconfirmed releases

Holder / event
Holder / eventTerm / dateConditions
Over-allotment windowPost-listing See filing · Additional shares only if exercisedOver-allotment window · Additional shares only if exercised
Insider resale eligibilityHolder-specific See 424B · Existing-holder supplyInsider resale eligibility · Existing-holder supply
Basis and evidence
Over-allotment window

Over-allotment window · Additional shares only if exercised

Lock-up / shares eligible for future sale ↗
Insider resale eligibility

Insider resale eligibility · Existing-holder supply

Lock-up / shares eligible for future sale ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

$ · Annual values as reported
FY2024($30,695,000)
FY2025($60,555,000)

Operating cash flow

$ · Annual values as reported
FY2024($31,416,000)
FY2025($46,925,000)
Financial quality
CalculationFY2024FY2025
Net income / (loss)($30,695,000)($60,555,000)
Operating cash flow($31,416,000)($46,925,000)
Financial quality
CalculationReported value
Cash and cash equivalents2024-12-31$100,147,000
Cash and cash equivalents2025-12-31$136,682,000
Current assets2024-12-31$104,172,000
Current assets2025-12-31$138,826,000
Total assets2024-12-31$106,775,000
Total assets2025-12-31$162,968,000
Current liabilities2024-12-31$6,773,000
Current liabilities2025-12-31$15,480,000
Total liabilities2024-12-31$6,773,000
Total liabilities2025-12-31$37,873,000
Total equity / (deficit)2024-12-31($72,883,000)
Total equity / (deficit)2025-12-31($131,728,000)
General and administrative expensesFY2024$4,591,000
General and administrative expensesFY2025$7,886,000
Cash and cash equivalents2025-12-31 · Unaudited$136,682,000
Cash and cash equivalents2026-03-31 · Unaudited$116,003,000
Current assets2025-12-31 · Unaudited$138,826,000
Current assets2026-03-31 · Unaudited$119,723,000
Total assets2025-12-31 · Unaudited$162,968,000
Total assets2026-03-31 · Unaudited$143,410,000
Current liabilities2025-12-31 · Unaudited$15,480,000
Current liabilities2026-03-31 · Unaudited$16,178,000
Total liabilities2025-12-31 · Unaudited$37,873,000
Total liabilities2026-03-31 · Unaudited$38,707,000
Total equity / (deficit)2025-12-31 · Unaudited($131,728,000)
Total equity / (deficit)2026-03-31 · Unaudited($152,120,000)
General and administrative expenses3M ended 2025-03-31 · Unaudited$1,882,000
General and administrative expenses3M ended 2026-03-31 · Unaudited$2,206,000
Net income / (loss)3M ended 2025-03-31 · Unaudited($10,478,000)
Net income / (loss)3M ended 2026-03-31 · Unaudited($21,008,000)
Operating cash flow3M ended 2025-03-31 · Unaudited($10,979,000)
Operating cash flow3M ended 2026-03-31 · Unaudited($20,940,000)
Basis and evidence
Cash and cash equivalents
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
General and administrative
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
General and administrative
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net loss
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net loss
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Cash and cash equivalents
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total stockholders’ deficit
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
General and administrative
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
General and administrative
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net loss
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net loss
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net cash used in operating activities
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net cash used in operating activities
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Saved snapshot — period not verified

These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.

Financial quality

Financial quality
CalculationReported value
RevenuePre-revenue
Net resultLatest reported$(71.09M)
Market-value referencePost-listing snapshot$501.94M
Shares outstandingLatest reported30.64M
Offer size9.375M$150.00M
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Financial reviewReported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open 424B4 ↗
Evidence 01Final prospectus source verified

Why it mattersChanges dilution, public float and potential supply.

Evidence · 424B4 · 2026/08/07
Evidence 02Trading began on 2026-08-07 at $16.00

Why it mattersChanges valuation, proceeds and first-day return assumptions.

Evidence · 424B4 · 2026/08/07
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.
2026/08/07
424B4

• Final prospectus source verified

• Trading began on 2026-08-07 at $16.00

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

Potential impact
High
Risk 4

Option exercise, employee equity and lock-up expiry can expand tradable supply.

Potential impact
Medium
Document424B4SEC source document
Filed2026-08-07SEC EDGAR
Research as of2026/08/071 public filings identified
Source-bound table inputs103SEC EDGAR
Open filing ↗
Sources and calculation notes

Final prospectus, offer price, listing date and headline financial evidence reconciled

View the filing's actual first page
BlossomHill Therapeutics, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR